4.0 Article

Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration

期刊

BRAIN COMMUNICATIONS
卷 4, 期 2, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/braincomms/fcac013

关键词

mild cognitive impairment; dementia with Lewy bodies; MRI; atrophy; prodromal DLB

资金

  1. National Institutes of Health [U01 NS100620, P50 AG16574, U01 AG06786, R01 AG11378]
  2. Foundation
  3. Mayo Clinic Dorothy and Harry T. Mangurian Jr Foundation for the Lewy Body Disease Research
  4. Lewy Body Dementia Association
  5. Little Family Foundation
  6. Turner Family Foundation
  7. Katherine B. Andersen Foundation

向作者/读者索取更多资源

This study found that prodromal dementia with Lewy bodies is characterized by atrophy in the nucleus basalis of Meynert. Longitudinally, grey matter atrophy progresses in regions with significant cholinergic innervation, with accelerated rates of atrophy in patients who progress to dementia with Lewy bodies.
This study demonstrated that prodromal dementia with Lewy bodies is characterized by atrophy in the nucleus basalis of Meynert. Longitudinally, grey matter atrophy progressed in regions with significant cholinergic innervation, in alignment with clinical disease progression, with accelerated rates of atrophy in patients who progressed to dementia with Lewy bodies. Mild cognitive impairment with the core clinical features of dementia with Lewy bodies is recognized as a prodromal stage of dementia with Lewy bodies. Although grey matter atrophy has been demonstrated in prodromal dementia with Lewy bodies, longitudinal rates of atrophy during progression to probable dementia with Lewy bodies are unknown. We investigated the regional patterns of cross-sectional and longitudinal rates of grey matter atrophy in prodromal dementia with Lewy bodies, including those who progressed to probable dementia with Lewy bodies. Patients with mild cognitive impairment with at least one core clinical feature of dementia with Lewy bodies (mean age = 70.5; 95% male), who were enrolled in the Mayo Clinic Alzheimer's Disease Research Center and followed for at least two clinical evaluations and MRI examinations, were included (n = 56). A cognitively unimpaired control group (n = 112) was matched 2:1 to the patients with mild cognitive impairment by age and sex. Patients either remained stable (n = 28) or progressed to probable dementia with Lewy bodies (n = 28) during a similar follow-up period and pathologic confirmation was available in a subset of cases (n = 18). Cross-sectional and longitudinal rates of grey matter atrophy were assessed using voxel-based and atlas-based region of interest analyses. At baseline, prodromal dementia with Lewy bodies was characterized by atrophy in the nucleus basalis of Meynert both in those who remained stable and those who progressed to probable dementia with Lewy bodies (P < 0.05 false discovery rate corrected). Increase in longitudinal grey matter atrophy rates were widespread, with greatest rates of atrophy observed in the enthorhinal and parahippocampal cortices, temporoparietal association cortices, thalamus and the basal ganglia, in mild cognitive impairment patients who progressed to probable dementia with Lewy bodies at follow-up (P < 0.05 false discovery rate corrected). Rates of inferior temporal atrophy were associated with greater rates of worsening on the clinical dementia rating-sum of boxes. Seventeen of the 18 (94%) autopsied cases had Lewy body disease. Results show that atrophy in the nucleus basalis of Meynert is a feature of prodromal dementia with Lewy bodies regardless of proximity to progression to probable dementia with Lewy bodies. Longitudinally, grey matter atrophy progresses in regions with significant cholinergic innervation, in alignment with clinical disease progression, with widespread and accelerated rates of atrophy in patients who progress to probable dementia with Lewy bodies. Given the prominent neurodegeneration in the cholinergic system, patients with prodromal dementia with Lewy bodies may be candidates for cholinesterase inhibitor treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据